Compare AUBN & LONA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AUBN | LONA |
|---|---|---|
| Founded | 1907 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.8M | 81.5M |
| IPO Year | 1996 | 2020 |
| Metric | AUBN | LONA |
|---|---|---|
| Price | $26.18 | $8.01 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 781.0 | ★ 46.6K |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.61% | N/A |
| EPS Growth | ★ 13.66 | N/A |
| EPS | ★ 1.29 | N/A |
| Revenue | ★ $619,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $20.26 | ★ N/A |
| Revenue Growth | ★ 0.81 | N/A |
| 52 Week Low | $21.60 | $4.21 |
| 52 Week High | $28.88 | $14.21 |
| Indicator | AUBN | LONA |
|---|---|---|
| Relative Strength Index (RSI) | 47.82 | 48.46 |
| Support Level | $25.09 | $6.86 |
| Resistance Level | $27.00 | $8.66 |
| Average True Range (ATR) | 0.22 | 0.56 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 28.92 | 26.72 |
Auburn National Bancorp Inc is a bank holding company registered with the Board of Governors of the Federal Reserve System (the Federal Reserve). As a bank holding company, the Company may diversify into a broader range of financial services and other business activities than are currently permitted to the Bank under applicable laws and regulations. The holding company structure also provides greater financial and operating flexibility than is presently permitted to the Bank. The Company's business is conducted through the Bank and its subsidiaries. Although it has no immediate plansto conduct any other business, the Company may engage directly or indirectly in several activities closely related to banking permitted by the Federal Reserve.
LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.